Latest revenue
$52.6M
as of 2026-03-31
Latest net income
$-27.4M
as of 2026-03-31
Net margin
-52.1%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.54B
- Enterprise value
- $2.54B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $41.22
- 52-wk low
- $20.13
- Beta
- —
- Shares out
- 86.2M
5-year trend
What this company does
Item 1. Business Overview We provide software and artificial intelligence (“AI”) designed to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of December 31, 2025, our Heartflow Platform has been used to assess CAD in more than 600,000 patients, including 219,000 in 2025 alone. We believe that we are the most widely adopted AI-powered test for CAD. Our novel platform leverages AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography (“CCTA”), a specialized type of scan that…
AI summary unavailable — showing raw filing excerpt
Generated from HTFL's filing dated 2026-03-18
Key risks
27 Table of Contents Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in, hold or sell our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, financial condition, results of operations and prospects. In such an event, the market price of our common…
AI summary unavailable — showing raw filing excerpt
Generated from HTFL's filing dated 2026-03-18
Profitability
Gross margin
76.8%
2.3%Operating margin
-36.4%
25.2%Net margin
-66.3%
13.4%Return on equity
-38.8%
446.3%Return on assets
-32.5%
60.0%Leverage
Debt / equity
0.20×
117.2%Long-term debt / equity
-0.16×
Debt / assets
16.4%
98.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $52.6M | +41.3% | $-27.4M | +15.4% | -52.1% |
Q4 2025 2025-12-31 | $49.1M | — | $-24.4M | — | -49.7% |
Q3 2025 2025-09-30 | $46.3M | +40.5% | $-50.9M | -165.7% | -109.9% |
Q2 2025 2025-06-30 | $43.4M | +39.8% | $-9.2M | +60.7% | -21.2% |
Q1 2025 2025-03-31 | $37.2M | — | $-32.3M | — | -86.9% |
Q3 2024 2024-09-30 | $32.9M | — | $-19.1M | — | -58.1% |
Q2 2024 2024-06-30 | $31.1M | — | $-23.4M | — | -75.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on HTFL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.1M
Insider selling
$123.0M
Net activity
−$121.9M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns HTFL
Institutional value
$399.9M
Total shares held
16.4M
Distinct holders
88
-23 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $49.8M | — | New |
| 2 | Invesco Ltd. | 1.9M | $46.5M | +1.3M (+231.3%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $46.1M | — | New |
| 4 | BlackRock, Inc. | 1.5M | $35.6M | +120.4K (+9.0%) | Added |
| 5 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.4M | $34.4M | -16.2K (-1.1%) | Trimmed |
| 6 | BAILLIE GIFFORD & CO | 1.1M | $26.4M | -1.9M (-63.9%) | Trimmed |
| 7 | FRANKLIN RESOURCES INC | 793.7K | $19.3M | +108.6K (+15.8%) | Added |
| 8 | Voya Investment Management LLC | 727.7K | $17.7M | +499.1K (+218.3%) | Added |
| 9 | Ensign Peak Advisors, Inc | 690.5K | $16.8M | -10.3K (-1.5%) | Trimmed |
| 10 | XXEC, Inc. | 557.4K | $16.3M | +515.4K (+1229.6%) | Added |
| 11 | Champlain Investment Partners, LLC | 567.4K | $13.8M | — | New |
| 12 | JPMORGAN CHASE & CO | 447.0K | $10.7M | -139.3K (-23.8%) | Trimmed |
| 13 | UBS Group AG | 429.1K | $10.4M | -72.1K (-14.4%) | Trimmed |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 342.8K | $8.3M | +334.2K (+3886.2%) | Added |
| 15 | EMERALD ADVISERS, LLC | 221.3K | $5.4M | -280 (-0.1%) | Trimmed |
| 16 | VANGUARD FIDUCIARY TRUST CO | 150.5K | $3.7M | — | New |
| 17 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 134.0K | $3.3M | — | New |
| 18 | EMERALD MUTUAL FUND ADVISERS TRUST | 131.3K | $3.2M | +0 (+0.0%) | No change |
| 19 | Lisanti Capital Growth, LLC | 123.8K | $3.0M | +80.0K (+182.7%) | Added |
| 20 | Quantbot Technologies LP | 120.8K | $2.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once HTFL's latest filing finishes processing.